Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gefitinib

FDA-approved product (tablet, oral), marketed as Gefitinib, Iressa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gefitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gefitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gefitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

    NCT01776684 · start 2012-06

    Registered record
    Registry ID
    NCT01776684
    Conditions
    EGFR Mutation Positive Non-small Cell Lung Cancer
    Interventions
    EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2012-06
    Completion
    2015-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEGFR Mutation Positive Non-small Cell Lung Cancer
    InterventionEGFR TKIs (gefitinib, erlotinib, afatinib, et al)
    PhaseNot applicable
    Registry statusUnknown

  • A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

    NCT01610336 · start 2012-04-05

    Registered record
    Registry ID
    NCT01610336
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    INC280; Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-04-05
    Completion
    2020-05-27
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionINC280; Gefitinib
    PhasePhase 2
    Registry statusCompleted

  • Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

    NCT01579630 · start 2011-03

    Registered record
    Registry ID
    NCT01579630
    Conditions
    NSCLC
    Interventions
    Pemetrexed 500mg/m2 iv; Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2011-03
    Completion
    2014-06
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionPemetrexed 500mg/m2 iv; Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

    NCT01192243 · start 2009-12

    Registered record
    Registry ID
    NCT01192243
    Conditions
    Toxicity; Non-small Cell Lung Cancer
    Interventions
    Gefitinib; Pemetrexed; Cisplatin or carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-12
    Completion
    Not recorded
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToxicity; Non-small Cell Lung Cancer
    InterventionGefitinib; Pemetrexed; Cisplatin or carboplatin
    PhasePhase 2
    Registry statusUnknown

  • Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

    NCT00614809 · start 2007-12

    Registered record
    Registry ID
    NCT00614809
    Conditions
    Non-Small Cell Lung Cancer; Brain Metastasis
    Interventions
    gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2007-12
    Completion
    2010-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Brain Metastasis
    Interventiongefitinib
    PhasePhase 2
    Registry statusUnknown

  • Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy

    NCT00497250 · start 2007-07

    Registered record
    Registry ID
    NCT00497250
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Gefitinib; Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2007-07
    Completion
    2009-10
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionGefitinib; Radiation Therapy
    PhasePhase 1
    Registry statusUnknown

  • Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

    NCT00522145 · start 2007-05

    Registered record
    Registry ID
    NCT00522145
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    XL647
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2010-02
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionXL647
    PhasePhase 2
    Registry statusCompleted

  • Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

    NCT00423397 · start 2006-09

    Registered record
    Registry ID
    NCT00423397
    Conditions
    Non-melanomatous Skin Cancer
    Interventions
    PEG-interferon alfa-2a; gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2006-09
    Completion
    Not recorded
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-melanomatous Skin Cancer
    InterventionPEG-interferon alfa-2a; gefitinib
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

    NCT00372515 · start 2006-06

    Registered record
    Registry ID
    NCT00372515
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Gefitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-06
    Completion
    2015-04
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionGefitinib
    PhasePhase 1
    Registry statusCompleted

  • Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

    NCT00570401 · start 2006-06

    Registered record
    Registry ID
    NCT00570401
    Conditions
    Lung Cancer
    Interventions
    dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-06
    Completion
    2011-09
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventiondasatinib
    PhasePhase 2
    Registry statusCompleted

  • First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia

    NCT00322452 · start 2006-03

    Registered record
    Registry ID
    NCT00322452
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Gefitinib; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2010-06
    Enrolment
    1,329

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionGefitinib; Carboplatin; Paclitaxel
    PhasePhase 3
    Registry statusCompleted

  • Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

    NCT00319800 · start 2006-02

    Registered record
    Registry ID
    NCT00319800
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Gefitinib; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2006-02
    Completion
    2007-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionGefitinib; Irinotecan
    PhasePhase 2
    Registry statusUnknown

  • Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer

    NCT00266877 · start 2005-12

    Registered record
    Registry ID
    NCT00266877
    Conditions
    Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
    Interventions
    HKI-272
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-12
    Completion
    2009-01
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung; Lung Neoplasms
    InterventionHKI-272
    PhasePhase 2
    Registry statusCompleted

  • Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

    NCT00258323 · start 2005-10

    Registered record
    Registry ID
    NCT00258323
    Conditions
    Esophageal Cancer
    Interventions
    cisplatin; fluorouracil; Iressa; conventional surgery; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    2010-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer
    Interventioncisplatin; fluorouracil; Iressa; conventional surgery +1 more
    PhasePhase 2
    Registry statusCompleted

  • PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)

    NCT00173524 · start 2005-09

    Registered record
    Registry ID
    NCT00173524
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    PharmacoEconomic Assessment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2005-09
    Completion
    2005-09
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionPharmacoEconomic Assessment
    PhaseNot recorded
    Registry statusUnknown